0.4883
Schlusskurs vom Vortag:
$0.4623
Offen:
$0.488
24-Stunden-Volumen:
419.23K
Relative Volume:
0.16
Marktkapitalisierung:
$20.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-74.56M
KGV:
-0.2666
EPS:
-1.8316
Netto-Cashflow:
$-60.27M
1W Leistung:
+17.95%
1M Leistung:
+59.31%
6M Leistung:
-44.02%
1J Leistung:
-63.01%
Rallybio Corp Stock (RLYB) Company Profile
Firmenname
Rallybio Corp
Sektor
Branche
Telefon
203- 859-3820
Adresse
234 CHURCH STREET, NEW HAVEN
Vergleichen Sie RLYB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RLYB
Rallybio Corp
|
0.4883 | 17.23M | 0 | -74.56M | -60.27M | -1.8316 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-05-15 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-02-07 | Herabstufung | Jefferies | Buy → Hold |
2023-04-17 | Eingeleitet | H.C. Wainwright | Buy |
2023-04-10 | Eingeleitet | Wedbush | Outperform |
2022-12-09 | Eingeleitet | JP Morgan | Overweight |
2022-02-22 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-08-23 | Eingeleitet | Cowen | Outperform |
2021-08-23 | Eingeleitet | Evercore ISI | Outperform |
2021-08-23 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Rallybio Corporation Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
What analysts say about Rallybio Corporation stockHigh-octane gains - jammulinksnews.com
What drives Rallybio Corporation stock priceUnmatched market gains - printweek.in
Is Rallybio Corporation a good long term investmentTremendous gains - jammulinksnews.com
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser
Why Rallybio Corporation stock attracts strong analyst attentionFree Join Group - Newser
How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - MSN
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -
Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest
Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa
Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com Nigeria
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz
RallyBio - Hartford Business Journal
Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks
Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech
Recursion Pharmaceuticals Acquires Full Interest in Joint Hypophosphatasia Candidate From Rallybio - MarketScreener
Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha
Rallybio sells interest in REV102 program to Recursion Pharmaceuticals - grafa.com
Rallybio Sells REV102 Program to Recursion Pharmaceuticals - TipRanks
ImmunoPrecise Strengthens Board with 30-Year Biotech Veteran Jon Lieber from Rallybio - Stock Titan
Finanzdaten der Rallybio Corp-Aktie (RLYB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):